Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
NCT ID: NCT00538187
Last Updated: 2015-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
18 participants
INTERVENTIONAL
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To establish the maximum tolerated dose of obatoclax mesylate when administered with bortezomib in patients with aggressive relapsed or recurrent non-Hodgkin lymphoma.
II. To describe the toxicities of this regimen at each dose studied in these patients.
III. To characterize the pharmacokinetic behavior of this regimen in these patients.
IV. To obtain preliminary information regarding the effect of obatoclax mesylate on several apoptotic regulatory pathways.
V. To document all clinical responses in these patients to this regimen.
OUTLINE: This is a multicenter study.
PHASE I: Patients receive obatoclax mesylate IV over 3 hours followed by bortezomib IV on days 1, 8, 15, and 22.
Treatment repeats every 35 days in the absence of disease progression or unacceptable toxicity. Pharmacokinetic evaluations of obatoclax mesylate are conducted in all patients during the first course.
PHASE II: Patients receive obatoclax mesylate IV over 3 hours followed by bortezomib IV on days 1, 8, 15, and 22 at the maximum tolerated dose determined in phase I.
Treatment repeats every 35 days for up to 1 year in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for 26 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (obatoclax mesylate, bortezomib)
Patients will receive a 3-hour infusion of obatoclax and an infusion of bortezomib once a week for 4 weeks
obatoclax mesylate
Given IV
bortezomib
Given IV
laboratory biomarker analysis
correlative study
pharmacological study
correlative study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
obatoclax mesylate
Given IV
bortezomib
Given IV
laboratory biomarker analysis
correlative study
pharmacological study
correlative study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Follicular grade I, II, or III lymphoma
* Marginal zone lymphoma
* Mantle cell lymphoma
* Diffuse large B cell lymphoma
* Small lymphocytic lymphoma
* Must have had at least one prior chemotherapeutic regimen:
* Steroids or rituximab alone or local radiotherapy do not count as regimens
* Tositumomab or ibritumomab tiuxetan allowed as regimens
* Clear evidence of disease progression or lack of response after the most recent therapy, including rituximab or local radiotherapy, is required
* At least 3 months since prior autologous stem cell transplantation and relapsed (\>= 1 year since prior allogeneic transplantation and relapsed) and no active related infections (i.e., fungal or viral)
* In the case of allogeneic transplantation relapse, there should be no active acute graft-versus-host disease (GVHD) of any grade and no chronic GVHD other than mild skin, oral, or ocular GVHD not requiring systemic immunosuppression
* No known active brain metastases, other neurological disorders/dysfunction or history of seizure disorder, or other neurological dysfunction
* Karnofsky performance status 60-100%
* Life expectancy \> 3 months
* Total bilirubin normal
* AST and ALT =\< 2.5 times upper limit of normal
* Creatinine normal or creatinine clearance \>= 60 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective double-barrier contraception during and for 3 months after the last dose of obatoclax mesylate
* At least 4 weeks since prior radiotherapy
* More than 2 days since prior steroids
* More than 2 weeks since prior low-dose chlorambucil
* WBC \>= 3,000/mm\^3
* ANC \>= 1,500/mm\^3
* Platelet count \>= 100,000/mm\^3
* At least 2 weeks since prior valproic acid
Exclusion Criteria
* Ongoing or active infection
* Symptomatic congestive heart failure
* Unstable angina pectoris
* Cardiac arrhythmia including QTc \> 450 msec
* Patients who are intolerant or refractory to prior treatment with bortezomib (refractory is defined as no response to prior treatment with bortezomib)
* Chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C)
* Rituximab within the past 3 months (unless there is evidence of progression)
* Patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier
* Other concurrent investigational agents
* Combination antiretroviral therapy for HIV-positive patients
* No history of allergic reactions attributed to bortezomib, polyethylene glycol (PEG 300), or polysorbate 20
* No psychiatric illness or social situation that would limit compliance with study requirements
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph Tuscano
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Medical Center
Duarte, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHI-58
Identifier Type: -
Identifier Source: secondary_id
CDR0000566357
Identifier Type: -
Identifier Source: secondary_id
NCI-2009-00253
Identifier Type: -
Identifier Source: org_study_id